27th Feb 2024 A plain language summary looking at spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP)
27th Feb 2024 A plain language summary looking at nivolumab that is given after stage 2B/2C melanoma is removed by surgery
25th Jan 2024 GATHER1 and GATHER2 studies: a plain language summary looking at whether avacincaptad pegol works and is safe in people with geographic atrophy
22nd Jan 2024 Two different concentrations of GP2017 (a biosimilar medicine) are associated with similar drug levels in the body- a plain language summary
22nd Jan 2024 A plain language summary of epicutaneous immunotherapy with Viaskin™ Peanut in toddlers
22nd Jan 2024 A plain language summary of the RACE study looking at adding eltrombopag to standard treatment of severe aplastic anemia
29th Sep 2023 A plain language summary of the PATHWAY and NAVIGATOR studies: tezepelumab for the treatment of severe asthma
6th Jul 2023 Plain Language Summary: ritlecitinib treatment for adults and adolescents with alopecia areata
27th Jun 2023 Plain Language Summary: what can clinical studies tell us about evobrutinib, a potential treatment for multiple sclerosis
2nd Jun 2023 Plain Language Summary: comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms
23rd May 2023 Plain Language Summary: POETYK PSO-1 study, treatment of plaque psoriasis with deucravacitinib
23rd May 2023 Plain Language Summary: treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study)
17th May 2023 Plain Language Summary: principles for improving the care of people with eosinophil-associated diseases
1st Mar 2023 Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn’s disease
20th Sep 2022 Plain language summary of the VOLTAIRE-RA study in patients with moderate-to-severe rheumatoid arthritis